Camurus is hoping for fast action on the reimbursement of its prolonged release subcutaneous injection BUVIDAL (buprenorphine) for opiate dependence. …
Latest Video
New Stories
-
Sanofi's Karen Hood: 'Industry needs a clear and specific plan'
October 14, 2019 - - Latest News -
Government backs new cell and tissue research facility
October 14, 2019 - - Latest News -
Industry 'right in the crosshairs'
October 14, 2019 - - Latest News -
Industry prepares to gather in Canberra for PharmAus19
October 14, 2019 - - Latest News -
New Cabinet Handbook brings forward Budget process
October 14, 2019 - - Latest News -
Lundbeck and Otsuka 'on the bridge' for mental health
October 14, 2019 - - Latest News -
Cancer and malaria the focus of new CSL Centenary Fellowships
October 11, 2019 - - Latest News